---
title: "Rafael Holdings reports Q3 financials; Cyclo Therapeutics' Phase 3 trial for Niemann-Pick Disease fully enrolled, results due this month."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/244058123.md"
description: "Cyclo Therapeutics has successfully enrolled all participants in the Phase 3 clinical trial of TransportNPC™ for the treatment of Niemann-Pick Disease Type C1. This rare genetic disease is known to be fatal. The trial involves the use of Trappsol® Cyclo™ and results from the 48-week interim analysis are anticipated to be released within the current month. This development marks a significant advancement in the efforts to combat this severe condition."
datetime: "2025-06-11T11:22:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/244058123.md)
  - [en](https://longbridge.com/en/news/244058123.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/244058123.md)
generator: "portal-rs"
---

# Rafael Holdings reports Q3 financials; Cyclo Therapeutics' Phase 3 trial for Niemann-Pick Disease fully enrolled, results due this month.

Cyclo Therapeutics has successfully enrolled all participants in the Phase 3 clinical trial of TransportNPC™ for the treatment of Niemann-Pick Disease Type C1. This rare genetic disease is known to be fatal. The trial involves the use of Trappsol® Cyclo™ and results from the 48-week interim analysis are anticipated to be released within the current month. This development marks a significant advancement in the efforts to combat this severe condition.

### Related Stocks

- [CYTH.US](https://longbridge.com/en/quote/CYTH.US.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**